Hospice & Palliative Care EBITDA Multiples: 3x–7x — What Buyers Pay (2026)
Medicare-certified hospice agencies with clean compliance records and stable census trade at 4x–7x EBITDA. Here's what moves the needle in lower middle market transactions.
Hospice and palliative care businesses in the $1M–$5M revenue range typically sell at 4x–7x EBITDA, driven by Medicare certification status, average daily census trends, referral source diversification, and compliance history. Private equity roll-up platforms and regional strategic acquirers dominate deal activity, and multiples are sensitive to OIG exposure, staff stability, and Medicare cap position. Clean operators with tenured clinical teams and diversified referral networks command premium valuations.
Hospice & Palliative Care EBITDA Multiples (2026)
| Practice Size | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed or Compliance-Impaired | $300K–$600K | 3x–4x | Active Medicare audits, RAC findings, high staff turnover, or referral concentration above 30% from a single source. Buyers price in significant remediation and compliance risk. |
| Average Operator | $400K–$800K | 4x–5x | Stable ADC, acceptable compliance record, moderate referral diversification, but limited accreditation, below-average length-of-stay metrics, or owner-dependent referral relationships. |
| Strong Independent Agency | $600K–$1.2M | 5x–6x | Growing ADC, clean survey history, diversified referral network, tenured clinical leadership, ACHC or CHAP accreditation, and well-documented financials with normalized EBITDA. |
| Premium Platform-Ready Asset | $900K–$1.5M | 6x–7x | Scalable operations, multi-site or multi-county footprint, favorable CON-free state, strong payer mix, zero active compliance issues, and management team willing to roll equity. |
Valuation Drivers — What Makes Your Multiple Higher or Lower
The spread between 3.5x and 6.5x is not random. These seven factors determine where your firm lands.
Medicare Cap Position
HighAgencies near or exceeding the Medicare annual per-beneficiary cap face revenue ceilings and billing scrutiny. Buyers heavily discount or restructure deals around unresolved cap exposure.
Average Daily Census Trends
HighA growing or stable ADC of 40–150 patients signals operational health. Declining ADC raises census volatility concerns and compresses buyer confidence in forward EBITDA projections.
Referral Source Diversification
HighNo single referral source exceeding 20% of admissions is a key buyer criterion. Over-concentration in one hospital, SNF, or physician creates post-acquisition revenue risk.
Clinical Staff Stability
Medium-HighTenured RNs, a stable Director of Nursing, and low contracted-staff ratios increase buyer confidence. High turnover or unfilled clinical positions signal operational fragility and integration risk.
Compliance and Survey History
HighClean CMS surveys, no OIG enforcement actions, and documented anti-kickback safe harbors for referral relationships materially expand the buyer pool and support premium multiples.
Recent Market Trends
PE-backed hospice roll-up activity accelerated through 2022–2024 as platforms compete for Medicare-certified agencies in non-CON states. Buyers are increasingly scrutinizing Medicare eligibility documentation following heightened OIG enforcement. Staffing cost inflation has compressed EBITDA margins, making normalized add-backs a central negotiation point. SBA 7(a) financing remains viable for owner-operator buyers targeting sub-$3M revenue agencies with clean compliance records.
Who Buys Hospice & Palliative Cares in 2026
Individual Operator / Search Fund
Entrepreneurship through acquisition (ETA), first-time buyers, industry-adjacent operators
What they want: Stable, transferable cash flow in a Hospice & Palliative Care. SBA-eligible business, strong revenue quality, and a seller available for a 12–18 month transition.
Pros for seller
- +SBA 7(a) financing means 10% buyer equity — faster than waiting for institutional capital
- +Buyer works inside the business, maintaining client and staff relationships
- +Deal structure is typically straightforward: cash at close plus seller note
Cons for seller
- −Lower multiples than PE buyers — typically at the low-to-mid end of the range
- −Requires meaningful seller involvement post-close for transition
- −SBA approval timeline adds 60–90 days to closing
PE-Backed Roll-Up Platform
Private equity consolidators building a Hospice & Palliative Care portfolio, regional or national platforms
What they want: Scale, operational quality, and geographic coverage. Strong revenue quality with minimal owner dependency. Clean financials, documented systems, and staff who can operate without the selling owner.
Pros for seller
- +All-cash close with no SBA financing contingency or approval delay
- +Highest multiples available for premium businesses
- +Equity rollover option — seller keeps 10–30% stake and participates in platform exit
Cons for seller
- −Extensive 90–150 day due diligence process
- −Post-close integration into a larger platform changes operating culture
- −Usually requires seller to remain in a leadership role for 12–24 months
Strategic Acquirer
Larger Hospice & Palliative Care operators, adjacent-industry buyers adding capacity or geography
What they want: Client relationships, staff, and market position that complement existing operations. revenue quality is especially valuable when it fills a gap the buyer cannot build organically.
Pros for seller
- +Can pay above-model multiples for strong strategic fit
- +Buyer already understands the business — diligence moves faster
- +Shorter transition requirement when operational overlap exists
Cons for seller
- −Fewer competing buyers — less negotiating leverage
- −Non-compete scope is typically broader than PE or individual deals
- −Operations and brand may change significantly post-close
Sample Hospice & Palliative Care Transactions
Medicare-certified independent hospice in Southeast, ADC of 65, clean survey history, diversified SNF and physician referral base, retiring founder-operator
$550K
EBITDA
5.5x
Multiple
$3.0M
Price
Midwest hospice agency, ADC of 110, CHAP-accredited, multi-county service area, tenured clinical team, PE platform add-on acquisition with equity rollover
$1.1M
EBITDA
6.5x
Multiple
$7.2M
Price
Small urban hospice, ADC of 38, single referral source at 35% of admissions, pending RAC audit review, buyer negotiated compliance escrow holdback
$380K
EBITDA
3.8x
Multiple
$1.4M
Price
EBITDA Valuation Estimator
Get your Hospice & Palliative Care business value range instantly
Industry: Hospice & Palliative Care · Multiples based on 4x–5x (Average Operator)
Powered by DealFlow OS
dealflow-os.com · Free M&A tools for every stage of the deal
How to Use These Multiples
For Sellers: 4-Step Valuation Walkthrough
- 1
Compile three years of P&L statements and tax returns that reconcile line by line — SBA lenders and institutional buyers both require this, and any unexplained gap triggers diligence delays or price renegotiation.
- 2
Build a normalized EBITDA schedule with every add-back documented: owner W-2 above a market-rate manager salary, personal expenses, one-time items, and non-recurring costs. Undocumented add-backs get cut.
- 3
Address your owner dependency before going to market — this is the most common reason Hospice & Palliative Care businesses receive offers at the low end of the 3x–7x range. Buyers identify it in diligence and reprice accordingly.
- 4
Quantify and document your revenue quality with supporting records: contracts, renewal histories, and client revenue breakdowns. This is the primary evidence for commanding a premium multiple — have it ready before the first buyer call.
For Buyers: Validate the Asking Multiple
- 1
Request trailing 12-month and 3-year P&L with bank statement backup before making an offer. If a Hospice & Palliative Care seller cannot produce reconciled financials, that signals what the full diligence process will look like.
- 2
Verify the revenue quality claims independently — pull contract copies, renewal documentation, and client-level revenue data. This is the primary driver of whether this Hospice & Palliative Care is worth 7x or 3x.
- 3
Assess owner dependency directly: ask which revenue or client relationships depend on the current owner personally, and what the transition plan is. An exit-ready seller has already worked through this.
- 4
Model your SBA debt service against verified EBITDA before signing the LOI. At current rates, a $1M SBA 7(a) loan runs approximately $13,000/month over 10 years — the business needs at least 1.25x debt service coverage after a market-rate manager salary.
Frequently Asked Questions
What EBITDA multiple should I expect when selling my hospice agency?
Most Medicare-certified hospice agencies in the $1M–$5M revenue range sell at 4x–7x EBITDA. Clean compliance records, growing ADC, and diversified referrals drive multiples toward the upper end.
How does Medicare cap exposure affect my hospice company's valuation?
Active or approaching cap exposure is a significant deal risk. Buyers will discount valuation, require escrow holdbacks, or restructure as earnouts until cap liability is resolved or quantified.
Do hospice acquisitions qualify for SBA financing?
Yes. Medicare-certified hospice agencies with clean financials and no active compliance investigations are generally SBA 7(a) eligible. Lenders scrutinize Medicare reimbursement history and payer mix carefully.
What deal structure is most common in hospice acquisitions?
Asset purchases with Medicare provider agreement novation are most common. Deals typically include a 10–20% seller note or earnout tied to census retention, with escrow holdbacks for compliance contingencies.
More Hospice & Palliative Care Guides
Related Reading
Find Hospice & Palliative Care businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
No credit card required